Acute Hemodynamic Index Predicts In-Hospital Mortality in Acute Decompensated Heart Failure.

Embora a insuficiência cardíaca aguda (ICA) esteja associada a mortalidade hospitalar significativa (em torno de 9-11% de acordo com a taxa de mortalidade no registro BREATHE) e altas taxas de reinternação após a alta, as opções para o manejo desses pacientes permanecem limitadas.[1]

Uma vez que a sobrevida global é determinada principalmente pelo manejo inicial, uma estratificação de risco individual precisa e precoce pode ajudar os médicos a escolher a intensidade do cuidado necessário e promover a tomada de decisões médicas feita sob medida, com melhora do prognóstico.[2]

O artigo de Castro et al.[3] fornece uma ferramenta simples, a ser utilizada à beira do leito, para estratificar a população de pacientes com ICA com fração de ejeção reduzida, com base no cálculo do índice hemodinâmico agudo (IHA) (IHA= )que morreram, o que alguns estudos sugerem estar associado a maior mortalidade, especialmente em pacientes com IC e fibrilação atrial.[7]

O achado de que a PAS baixa estava associada à mortalidade também é consistente com outros estudos que demonstraram a importância prognóstica desse parâmetro, provavelmente porque PAS baixa e pressão de pulso estreita proporcional são marcadores de hipoperfusão.[7] O registro OPTIMIZE-HF[4] mostrou que valores de PAS abaixo de 120 mmHg caracterizavam os pacientes com ICA que apresentavam prognóstico desfavorável apesar da terapia medicamentosa, mas no estudo atual, a pressão arterial abaixo de 120 mmHg não foi independentemente relacionada à mortalidade em uma análise multivariada.

Hipotetizaram que a PAS elevada na admissão observada na maioria dos pacientes com ICA pode estar relacionada à ativação neuro-hormonal e de citocinas resultando em pós-carga aumentada, mas a fisiopatologia pode diferir em pacientes que apresentam PAS baixa e, consequentemente, pressão de pulso baixa, o que mais provavelmente pode significar doença em estágio avançado ou terminal com baixo débito cardíaco e sinais de hipoperfusão de órgãos. Também é razoável supor que pacientes com uma PAS elevada podem responder mais favoravelmente a vasodilatadores e antagonistas neuro-hormonais. No entanto, nenhum dos agentes farmacológicos estudados em ensaios recentes (vasodilatadores, inodilatadores e sensibilizadores de cálcio) melhorou os resultados clínicos.[5 , 8]

Além disso, a maioria das estimativas de risco foram derivadas de conjuntos de dados de ensaios clínicos, que podem não ser representativos de grandes populações de pacientes internados por IC.[1] Além disso, o número de variáveis e funções matemáticas envolvidas frequentemente requerem acesso a um computador ou calculadora eletrônica para gerar um escore e determinar o risco, tornando-os impraticáveis para avaliação à beira do leito, e dependem da medição de biomarcadores, treinamento da equipe médica e tecnologia que pode não estar amplamente disponível.[4 , 9] Em contraste, as medidas de FC e PA estão disponíveis em praticamente todos os locais de serviços de saúde com boa precisão e requerem treinamento mínimo, o que torna o IHA um marcador prognóstico prático, objetivo e de fácil obtenção.

Algumas limitações deste estudo devem ser reconhecidas. Este foi um estudo observacional incluindo menos de 500 pacientes, potencialmente não representativo de toda a população de pacientes com ICA e seus achados devem ser considerados como geradores de hipóteses e posteriormente validados em estudos prospectivos em outras populações.

Os resultados de estudos baseados em registros, como o Registro BREATHE, podem ajudar adicionalmente a definir modelos úteis para o desenho de ensaios clínicos para avaliar terapias para IC, uma vez que permitem que o risco seja equilibrado entre os grupos de tratamento e permitem critérios de inclusão seletivos para incluir apenas pacientes com alto risco de mortalidade intra-hospitalar. Eles também contribuem para o desenvolvimento de um modelo de predição de risco clínico para ICA, permitindo que os médicos estejam mais bem equipados para otimizar a utilização de recursos hospitalares com base em estimativas de risco específicas do paciente e, adicionalmente, as decisões terapêuticas podem eventualmente ser guiadas por estimativas de risco. Pacientes com estimativa de menor risco podem ser tratados com monitoramento menos intensivo e terapias disponíveis em uma unidade de telemetria ou enfermaria de hospital, enquanto um paciente com maior risco estimado pode necessitar de tratamento mais intensivo em uma unidade de terapia intensiva ou coronariana.[2] Entretanto, devemos ter em mente que esses modelos aprimoram, mas não substituem, a avaliação do médico.

Although acute heart failure (AHF) is associated with significant in-hospital mortality (around 9-11% in concordance with the mortality rate in the BREATHE registry) and high rates of rehospitalization after discharge, options for the management of these patients remain limited.[1]

Since overall survival is mainly determined by the initial management, accurate and early individual risk stratification can help physicians choose the intensity of care required and promote tailored medical decision-making with improvement of prognosis.[2]

The manuscript by Castro et al.[3]provides a simple, bedside tool, to stratify the population of patients with AHF with reduced ejection fraction, based on the calculation of the acute hemodynamic index (AHI) (AHI= ) at admission. The authors report that patients with low AHI (≤ 4 mmHg bpm) had an in-hospital mortality that was 2.5 times higher than patients with an higher AHI.

In the present analysis from the BREATHE registry only patients with evidence of left ventricle ejection fraction below 40% were included, contrary to most of the previous publications. Although previous studies, generally based on outpatients with chronic heart failure (HF), have identified a number of variables that are associated with increased mortality, including etiology, patient age, peak oxygen consumption, left ventricular ejection fraction, serum sodium concentration, and B-type natriuretic peptide concentration, several factors have limited the development of similar models in patients with AHF, such as lack of a consistent definition of AHF, incomplete data in administrative data sets, and varying statistical methods. Consequently, unlike acute coronary syndromes, in which several systems have been developed for risk stratification, no clinically practical method of risk stratification exists for patients with AHF.[4]

Results from the American multicenter ADHERE HF Registry identified blood urea nitrogen level, systolic blood pressure (SBP), heart rate (HR), and age as the most significant predictors of mortality in patients with AHF.[1]Others studies have also shown that an increased HR predicts prognosis in patients presenting with HF.[5]Autonomic imbalance resulting from sympathetic overactivity and parasympathetic withdrawal is likely to be the underlying mechanism of increased HR in HF. Several pathophysiologic mechanisms, including increased myocardial oxygen consumption, reduced diastolic filling times, compromised coronary perfusion with induction of myocardial ischemia, and precipitation of rhythm disturbances have been proposed to explain the association between higher HR and worse outcomes.[2]However, it has also been demonstrated that chronotropic incompetence, especially in patients with chronic HF, is associated with reduced functional capacity and poor survival.[6]In the present study an higher HR was not associated with worse outcomes. In fact, patients who died had a mean HR of 82 bpm at admission while those who survived had 90 bpm. Nevertheless, in the multivariate analysis HR was not an independent predictor of mortality. The association between a lower HR and mortality was unexpected and we can speculate that this might be due to the higher prevalence of treatment with digitalis in patients who died, which some studies suggest to be associated with higher mortality, especially in patients with HF and atrial fibrillation.[7]

The finding that low SBP was associated with mortality is also consistent with other studies that have demonstrated the prognostic importance of this parameter, probably because low SBP and narrow proportional pulse pressure are markers of hypoperfusion.[7]The OPTIMIZE-HF[4]registry found that SBP values below 120 mmHg characterized patients with AHF who had poor prognosis despite medical therapy, but in the current study, blood pressure below 120 mmHg was not independently related to mortality in a multivariate analysis. It has been hypothesized that the elevated SBP at admission observed in the majority of AHF patients may be related to neurohormonal and cytokine activation resulting in increased afterload, but the pathophysiology may differ in patients presenting with low SBP and consequently low pulse pressure, who may be more likely to have advanced or end-stage disease with low cardiac output and signs of organ hypoperfusion. It is also reasonable to hypothesize that patients with an elevated SBP may respond more favorably to vasodilators and neurohormonal antagonists. Nevertheless, none of the pharmacologic agents studied in recent trials (vasodilators, inodilators, and calcium sensitizers) has improved clinical outcomes.[5 , 8]

In addition, most risk estimates have been derived from clinical trial datasets, which may not be representative of broad populations of patients admitted for HF.[1]Also, the number of variables and mathematical functions involved frequently require access to a computer or an electronic calculator to generate a score and to determine risk, making them impractical for bedside assessment, and rely on biomarker measurement, medical staff training, and technology that may not be widely available.[4 , 9]In contrast, HR and BP measurements are available in virtually any healthcare facility with good accuracy and requiring minimal training, which makes AHI a practical, objective, and easily obtained prognostic marker.

Some limitations of this study should be acknowledged. It was an observational study including less than 500 patients, potentially not representative of the whole population of patients with AHF and its findings should be considered hypothesis-generating and subsequently validated in prospective studies in other populations.

The results of registry-based studies, like the BREATHE Registry, may additionally help to define models useful for the design of clinical trials to evaluate HF therapies, since they permit risk to be balanced across treatment groups and allow for selective inclusion criteria in order to enroll only patients at high risk for in-hospital mortality. They also contribute to the development of a clinical risk prediction model for AHF allowing clinicians to be better equipped to optimize in-hospital resource utilization based on patient-specific risk estimates, and additionally therapeutic decisions may eventually be guided by risk estimates as well. Patients estimated to be at a lower risk can be managed with less intensive monitoring and therapies available on a telemetry unit or hospital ward, whereas a patient estimated to be at a higher risk may require more intensive management in an intensive or coronary care unit.[2]Nevertheless, we should bear in mind that these models enhance, but don’t replace, physician assessment.